Antiviral therapy of hepatitis C

Scandinavian Journal of Gastroenterology, Supplement

Volumn 32, Issue 223, 1997, Pages 46-49

  Schalm, S W ^a   Brouwer, J T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic hepatitis; Combination therapy; Hepatitis C; Interferon; Ribavirin; Therapy; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN; URSODEOXYCHOLIC ACID; VIRUS RNA;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEPATITIS C; HUMAN; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; ARTICLE;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; RIBAVIRIN;

EID: 0030625190     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Poel van der CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994;334:1475-9.
2. Bresters D, Mauser-Bunschoten EP, Reesink HW, Roosendaal G, Poel van der CL, Chamuleau RA, et al. Sexual transmission of hepatitis C virus. Lancet 1993;342:210-1.
3. Meisel H, Reip A, Faltus B, Lu M, Porst H, Wiese M, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995;345:1209-11.
4. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899-905.
5. Wiese M. Natural course of hepatitis C. Study in an unselected group with identical infection. J Hepatol 1996;25 Suppl 1:57.
6. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 1993;119:110-5.
7. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
8. Brouwer JT, Nevens F, Kleter GEM, Elewaut A, Adler M, Brenard R, et al. Efficacy of interferon dose and factors predictive of response in chronic heaptitis C; final results of the Benelux Multicentre Study in 336 patients. Submitted for publication.
9. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer Jr HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989;321:1501-6.
10. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 1989;321:1506-10.
11. Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, TVVH Study Group. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993;17 Suppl 3:S123-6.
12. Ryff JC. Usefulness of interferon for treatment of hepatitis C. J Hepatol 1995;22 Suppl 1:101-9.
13. Lino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon α-2b. Dig Dis Sci 1993;38:612-8.
14. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Multicenter Study Group. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
15. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-61.
16. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yrdaydin C, et al. Ribavirin as therapy for chronic hepatitis C. A randomized double blind, placebo controlled trial. Ann Int Med 1995;123:897-903.
17. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996:In press.
18. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alpha for alpha-interferon resistant chronic hepatitis C. Gastroenterology 1994;107:812-7.
19. Brouwer JT, Nevens F, Michielsen P, Hautekeete ML, Chamuleau RAF, Adler M, et al. What options are left when hepatitis C does not respond to Interferon? Placebo-controlled Benelux multicentre trial on Ribavirin mono-therapy versus prolonged combination with Interferon. J Hepatol 1994;21:S17.
20. Chemello L, Cavaletto L, Bernardinello E, Silvestri E, Benvegnu L, Pontisso P, Albert A. Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes. J Hepatol 1994;21:S12.
21. Bellobuono A, Tempini S, Bellati G, Asti L, Ideo G. Ribavirin followed by alpha-interferon in chronic hepatitis C resistant to therapy. Gastroenterology 1995;108:A1033.
22. Schvarcz R, Ando Y, Sönnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995;23 Suppl 2:17-21.
23. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-12.
24. Schalm SW, Brouwer JT, Chemello L, Alberti A, Bellobuono A, Ideo G, et al. Interferon-ribavirin combination therapy for chronic hepatitis C. Dig Dis Sci 1996;41 Suppl:131-4.
25. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the effect, but not the toxicity of interferon in chronic hepatitis C: a meta-analysis of individual European patients. J Hepatol 1997:In press.
26. Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995;21:322-7.